Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

ConferencepositiveEP-104GIPositive

AI Analysis

Summary

Eupraxia Pharmaceuticals reported Q2 2026 financial results and presented data at Digestive Disease Week showing EP-104GI improved fibrosis and inflammation following single treatment administration.

Outcome Details

Data presented at Digestive Disease Week demonstrating improvement of fibrosis and inflammation following single treatment

Importance:5/10

Sentiment:

0.60

Q2 2026 ResultsConference PresentationDDW 2026EP-104GIFibrosisInflammation

Related Companies

$EPRX

Read the original article

Published by GlobeNewswire Pharma on August 11, 2026 9:21 PM

Read Original